

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Bulevirtide for treating chronic hepatitis D ID3732

Final stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • MYR Pharmaceuticals (bulevirtide) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Addenbrookes Liver Transplant Association • Black Health Agency • British HIV Association (BHIVA) • British Liver Trust • Compass UK • GMFA - The Gay Men's Health Charity • Haemophilia Society • Hepatitis B Foundation UK • Hepatitis C Trust • Liver4Life • Muslim Council of Britain • NAM • National AIDS Trust • South Asian Health Foundation • Specialised Healthcare Alliance • Terrence Higgins Trust • We Are With You <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Clinical Biochemists - Microbiology Section • Association of Surgeons of Great Britain and Ireland • Association of Clinical Microbiologists • British Association for Sexual Health and HIV • British Association for the Study of the Liver • British Blood Transfusion Society • British Committee for Standards in Haematology 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services - Jehovah's Witnesses • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Peginterferon alfa-2a (Roche) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Hepato-Biliary Group • Cochrane Infectious Diseases Group • Foundation for Liver Research • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • UCL Centre for Sexual Health & HIV Research • UK National Screening Committee

Final stakeholder list for the technology appraisal of bulevirtide for treating chronic hepatitis D - ID3732.
Issue date: March 2021

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Geriatrics Society • British Infection Association • British Liver Nurses Association • British Society for Haematology • British Society of Gastroenterology • Haemophilia Nurses Association • Infection Prevention Society • Medical Foundation for AIDS & Sexual Health • Microbiology Society • National Association of Primary Care • NHS Blood and Transplant • Positive Prevention Plus • Primary Care Society for Gastroenterology • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Virology Network • UK Clinical Pharmacy Association • UK Haemophilia Centre Doctors' Organisation • UK Harm Reduction Alliance <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Barking & Dagenham CCG • NHS England • NHS Northumberland CCG • Welsh Government 	<p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that manufactures the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that manufactures the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.